These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 11809985)

  • 1. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
    Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
    Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
    Waters JS; O'Brien ME
    Br J Cancer; 2002 Aug; 87(5):481-90. PubMed ID: 12189541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
    Ferrigno D; Buccheri G
    Lung Cancer; 2000 Aug; 29(2):91-104. PubMed ID: 10963840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for non-platinum chemotherapy in advanced NSCLC.
    Murren JR
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC.
    Gridelli C; Hainsworth J
    Lung Cancer; 2002 Dec; 38 Suppl 4():37-41. PubMed ID: 12480193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
    Bunn PA; Kelly K
    Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gemcitabine].
    Takeda K
    Nihon Rinsho; 2002 May; 60 Suppl 5():359-65. PubMed ID: 12101689
    [No Abstract]   [Full Text] [Related]  

  • 9. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL; Hurst M
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer.
    Lynch TJ
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):5-9. PubMed ID: 11444253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising new agents in the treatment of non-small cell lung cancer.
    Edelman MJ; Gandara DR
    Cancer Chemother Pharmacol; 1996; 37(5):385-93. PubMed ID: 8599859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
    Verma S; Ilersich AL
    Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New cytostatics in the therapy of non-small cell bronchial carcinoma].
    Serke M; Schönfeld N; Loddenkemper R
    Pneumologie; 1998 Jun; 52(6):333-7. PubMed ID: 9715648
    [No Abstract]   [Full Text] [Related]  

  • 14. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
    Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of docetaxel in advanced non-small-cell lung cancer.
    Belani CP; Eckardt J
    Lung Cancer; 2004 Dec; 46 Suppl 2():S3-11. PubMed ID: 15698529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment.
    Meert AP; Berghmans T; Branle F; Lemaître F; Mascaux C; Rubesova E; Vermylen P; Paesmans M; Sculier JP
    Anticancer Res; 1999; 19(5C):4379-90. PubMed ID: 10650780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
    Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
    Rigas JR
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):15-20. PubMed ID: 11441410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
    Georgoulias V; Scagliotti G; Miller V; Eckardt J; Douillard JY; Manegold C
    Semin Oncol; 2001 Feb; 28(1 Suppl 2):15-21. PubMed ID: 11284620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.